---
title: "Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/45075524.md"
description: "JILIN, China, Nov. 13, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the &#34;Company&#34; or &#34;Zhengye&#34;), a veterinary vaccine manufacturer that encompasses research, development,..."
datetime: "2026-11-14T13:11:24.000Z"
locales:
  - [en](https://longbridge.com/en/topics/45075524.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/45075524.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/45075524.md)
author: "[News_Caijian](https://longbridge.com/en/profiles/13299296.md)"
generator: "portal-rs"
---

# Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal

JILIN, China, Nov. 13, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its unaudited financial results for the six months ended June 30, 2026.

Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "During the first half of fiscal year 2026, we continued to enhance profitability through disciplined cost management and operational efficiency. Despite the decline in net revenue and gross profit, we are encouraged by the improvement in our gross profit margin to 32.9%, an increase of 1.8 percentage points from 31.1% in the same period last year, primarily reflecting improved margins in our other vaccines segment. Total operating expenses decreased by 22.2% year over year to RMB37.6 million, while our operating loss narrowed by 27.9%. Our net loss also decreased by 13.3% to RMB22.2 million from RMB25.6 million in the same period last year. Looking ahead, we aim to continue prioritizing financial discipline, optimizing our cost structure, and allocating resources efficiently to support sustainable growth and long-term value creation."

Mr. Aiden Han, co-chief executive officer of Zhengye, added, "We remain focused on advancing our long-term growth strategy through the development of high-demand vaccines and expansion into new markets. Building on our existing product development initiatives, we aim to further expand our presence in the household animal vaccine industry, including through the development of vaccines for cats and dogs. On the international front, with our products already exported to Vietnam, Pakistan, and Egypt, we intend to explore additional opportunities in Africa, Central Asia, and West Asia. We also aim to strengthen our ability to attract, incentivize, and retain talented professionals to support our long-term development. We believe these strategic initiatives, together with our established industry experience and technological capabilities, will enhance our competitiveness and support Zhengye's long-term growth."

**First Six Months of Fiscal Year 2026 Financial Summary**

-   Net revenue was RMB50.9 million (US$7.5 million) for the six months ended June 30, 2026, compared to RMB62.3 million for the same period last year.
-   Gross profit was RMB16.7 million (US$2.5 million) for the six months ended June 30, 2026, compared to RMB19.4 million for the same period last year.
-   Gross profit margin was 32.9% for the six months ended June 30, 2026, an increase of 1.8 percentage points from 31.1% for the same period last year.
-   Net loss was RMB22.2 million (US$3.3 million) for the six months ended June 30, 2026, compared to RMB25.6 million for the same period last year.
-   Basic and diluted loss per share was RMB0.40 (US$0.06) for the six months ended June 30, 2026, compared to RMB0.46 for the same period last year.

**First Six Months of Fiscal Year 2026 Financial Results**

***Net Revenue***

Net revenue was RMB50.9 million (US$7.5 million) for the six months ended June 30, 2026, representing a decrease of 18.3% from RMB62.3 million for the same period last year.

**For the six months ended June 30, (Unaudited)**

**2025**

**2026**

**(in thousands, except for percentages)**

**Revenues**

**RMB**

**%**

**RMB**

**US$**

**%**

Swine vaccines

46,706

74.9

38,202

5,630

75.0

Poultry vaccines

7,015

11.3

6,496

957

12.8

Other vaccines

8,607

13.8

6,249

922

12.2

**Total revenues**

**62,328**

**100**

**50,947**

**7,509**

**100**

-   Revenue from sales of swine vaccines was RMB38.2 million (US$5.6 million) for the six months ended June 30, 2026, decreased from RMB46.7 million for the same period last year. Amid the broader industry environment, cost-cutting requirements from key customers resulted in lower sales volume.
-   Revenue from sales of poultry vaccines was RMB6.5 million (US$1.0 million) for the six months ended June 30, 2026, decreased from RMB7.0 million for the same period last year. This decline was primarily due to lower sales volume amid weak market demand in the broader industry environment.
-   Revenue from sales of other vaccines was RMB6.2 million (US$0.9 million) for the six months ended June 30, 2026, decreased from RMB8.6 million for the same period last year. Lower demand from key customers resulted in reduced sales volume.

***Cost of Revenue***

Cost of revenue was RMB34.2 million (US$5.0 million) for the six months ended June 30, 2026, representing a decrease of 20.4% from RMB42.9 million for the same period last year.

***Gross Profit***

Gross profit was RMB16.7 million (US$2.5 million) for the six months ended June 30, 2026, decreased from RMB19.4 million for the same period last year.

Gross profit margin was 32.9% for the six months ended June 30, 2026, representing an increase of 1.8 percentage points from 31.1% for the same period last year. The increase in gross profit margin was primarily attributable to other vaccines, the gross profit margin of which improved from negative 20.8% for the six months ended June 30, 2025 to 0.4% for the six months ended June 30, 2026, mainly because the sales volume of sheep vaccines, which carry relatively high unit costs and fixed production costs, decreased amid weak market demand. The gross profit margins of swine vaccines and poultry vaccines remained relatively stable, at 44.3% and negative 2.9%, respectively, for the six months ended June 30, 2026, as compared to 45.9% and negative 3.8%, respectively, for the six months ended June 30, 2025.

***Operating Expenses***

Total operating expenses were RMB37.6 million (US$5.5 million) for the six months ended June 30, 2026, decreased from RMB48.3 million for the same period last year.

-   Sales and marketing expenses were RMB18.6 million (US$2.7 million) for the six months ended June 30, 2026, decreased from RMB23.2 million for the same period last year. The decrease in sales and marketing expenses mainly resulted from a decrease in payroll for sales staff and travel expenses.
-   General and administrative expenses were RMB13.7 million (US$2.0 million) for the six months ended June 30, 2026, decreased from RMB16.8 million for the same period last year. The decrease in administrative expenses was attributed to the decrease in employee compensation, professional service fees and travel expenses. The decrease in professional service fees was mainly because the Company incurred such fees in connection with the preparation for the Company's initial public offering for the six months ended June 30, 2025, while no such fees were incurred for the six months ended June 30, 2026.
-   Research and development expenses were RMB4.8 million (US$0.7 million) for the six months ended June 30, 2026, decreased from RMB9.0 million for the same period last year. The decrease in research and development expenses mainly resulted from a decrease in development material expenses and the absence of one-time bonuses paid to research and development personnel in connection with the Company's initial public offering in the current period.

***Net Loss***

Net loss was RMB22.2 million (US$3.3 million) for the six months ended June 30, 2026, decreased from RMB25.6 million for the same period last year.

***Basic and Diluted Loss per Share***

Basic and diluted loss per share was RMB0.40 (US$0.06) for the six months ended June 30, 2026, compared to RMB0.46 for the same period last year.

**Financial Condition**

As of June 30, 2026, the Company had cash of RMB31.9 million (US$4.7 million), compared to RMB50.3 million as of December 31, 2025.

Net cash used in operating activities was RMB16.8 million (US$2.5 million) for the six months ended June 30, 2026, compared to RMB14.0 million for the same period last year.

Net cash used in investing activities was RMB5.7 million (US$0.8 million) for the six months ended June 30, 2026, compared to RMB0.7 million for the same period last year.

Net cash provided by financing activities was RMB4.6 million (US$0.7 million) for the six months ended June 30, 2026, compared to RMB 42.3 million for the same period last year.

**Exchange Rate Information**

This announcement contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of Renminbi ("RMB") into U.S. dollars ("US$") were made at RMB6.7851 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on June 30, 2026.

### Related Stocks

- [ZYBT.US](https://longbridge.com/en/quote/ZYBT.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**